AU2019234580B2 - IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy - Google Patents

IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy Download PDF

Info

Publication number
AU2019234580B2
AU2019234580B2 AU2019234580A AU2019234580A AU2019234580B2 AU 2019234580 B2 AU2019234580 B2 AU 2019234580B2 AU 2019234580 A AU2019234580 A AU 2019234580A AU 2019234580 A AU2019234580 A AU 2019234580A AU 2019234580 B2 AU2019234580 B2 AU 2019234580B2
Authority
AU
Australia
Prior art keywords
cells
cell
nucleic acid
sequence
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019234580A
Other languages
English (en)
Other versions
AU2019234580A1 (en
Inventor
Michael C. Jensen
Adam Johnson
Giacomo TAMPELLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of AU2019234580A1 publication Critical patent/AU2019234580A1/en
Application granted granted Critical
Publication of AU2019234580B2 publication Critical patent/AU2019234580B2/en
Priority to AU2024202681A priority Critical patent/AU2024202681A1/en
Assigned to SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE reassignment SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE Amend patent request/document other than specification (104) Assignors: Seattle Children's Hospital (dba Seattle Children's Research Institute)
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
AU2019234580A 2018-03-14 2019-03-12 IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy Active AU2019234580B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202681A AU2024202681A1 (en) 2018-03-14 2024-04-24 IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643139P 2018-03-14 2018-03-14
US62/643,139 2018-03-14
PCT/US2019/021833 WO2019178085A1 (en) 2018-03-14 2019-03-12 Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202681A Division AU2024202681A1 (en) 2018-03-14 2024-04-24 IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy

Publications (2)

Publication Number Publication Date
AU2019234580A1 AU2019234580A1 (en) 2020-10-08
AU2019234580B2 true AU2019234580B2 (en) 2024-02-01

Family

ID=67907266

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019234580A Active AU2019234580B2 (en) 2018-03-14 2019-03-12 IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy
AU2024202681A Pending AU2024202681A1 (en) 2018-03-14 2024-04-24 IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202681A Pending AU2024202681A1 (en) 2018-03-14 2024-04-24 IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy

Country Status (13)

Country Link
US (1) US12606603B2 (https=)
EP (2) EP4491718A3 (https=)
JP (2) JP7314161B2 (https=)
KR (2) KR102917671B1 (https=)
CN (1) CN112088165A (https=)
AU (2) AU2019234580B2 (https=)
BR (1) BR112020018534A2 (https=)
CA (1) CA3093791A1 (https=)
EA (1) EA202091984A1 (https=)
IL (1) IL277268A (https=)
MX (2) MX2020009464A (https=)
SG (1) SG11202008926RA (https=)
WO (1) WO2019178085A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765041A4 (en) 2018-03-14 2021-12-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY
EP4577575A1 (en) * 2022-08-25 2025-07-02 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044811A1 (en) * 2014-09-19 2016-03-24 City Of Hope COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2
US20170209543A9 (en) * 2005-11-16 2017-07-27 City Of Hope Chimeric Immunoreceptor Useful in Treating Human Cancers
US20170224733A1 (en) * 2016-02-05 2017-08-10 City Of Hope Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
KR101763499B1 (ko) 2012-11-07 2017-07-31 화이자 인코포레이티드 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체
US9758807B2 (en) 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
CA2992989A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
WO2017040930A2 (en) * 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
US12304935B2 (en) * 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
AU2017319702B2 (en) 2016-09-02 2024-11-14 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US12083148B2 (en) 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
EP3765041A4 (en) 2018-03-14 2021-12-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209543A9 (en) * 2005-11-16 2017-07-27 City Of Hope Chimeric Immunoreceptor Useful in Treating Human Cancers
WO2016044811A1 (en) * 2014-09-19 2016-03-24 City Of Hope COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2
US20170224733A1 (en) * 2016-02-05 2017-08-10 City Of Hope Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System

Also Published As

Publication number Publication date
BR112020018534A2 (pt) 2020-12-29
MX2020009464A (es) 2021-01-15
EP3765487A1 (en) 2021-01-20
CN112088165A (zh) 2020-12-15
SG11202008926RA (en) 2020-10-29
AU2019234580A1 (en) 2020-10-08
JP2021518111A (ja) 2021-08-02
JP2023134631A (ja) 2023-09-27
US12606603B2 (en) 2026-04-21
US20210017246A1 (en) 2021-01-21
WO2019178085A1 (en) 2019-09-19
CA3093791A1 (en) 2019-09-19
KR20200131851A (ko) 2020-11-24
EA202091984A1 (ru) 2021-02-18
EP4491718A2 (en) 2025-01-15
IL277268A (en) 2020-10-29
EP3765487A4 (en) 2022-01-05
JP7696958B2 (ja) 2025-06-23
EP4491718A3 (en) 2025-03-26
MX2025010440A (es) 2025-10-01
KR102917671B1 (ko) 2026-01-27
JP7314161B2 (ja) 2023-07-25
AU2024202681A1 (en) 2024-05-16
KR20260021083A (ko) 2026-02-12

Similar Documents

Publication Publication Date Title
JP6788573B2 (ja) メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
AU2018207281B2 (en) Modulating expression of polypeptides via new gene switch expression systems
KR102617238B1 (ko) Fc-엡실론 car(fc-epsilon car)
CN111479921B (zh) 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物
KR102437015B1 (ko) 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
AU2015374296B2 (en) Methods of making chimeric antigen receptor-expressing cells
AU2018273979B2 (en) CBLB endonuclease variants, compositions, and methods of use
WO2018026819A2 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
KR20190058509A (ko) 융합 단백질을 이용하는 t-세포 수용체 리프로그래밍을 위한 조성물 및 방법
CN116057181A (zh) 用于修饰和递送淋巴细胞的方法和组合物
Chambers et al. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
AU2024202681A1 (en) IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy
EP3746116A1 (en) Combination therapy using a chimeric antigen receptor
KR20200110326A (ko) Daric 인터류킨 수용체
JP2025169261A (ja) 新規ドミナントネガティブｆａｓポリペプチド、それらを含む細胞、及びそれらの使用
AU2017347685B2 (en) TAL-effector nuclease (TALEN) -modified allogenic cells suitable for therapy
RU2848216C2 (ru) Лентивирус для получения клеток, экспрессирующих химерный антигенный рецептор против cd19
WO2025194140A1 (en) Thermally controlled gene expression and uses thereof
RU2792187C2 (ru) Композиции cart-иринов и способы их применения
WO2026006767A1 (en) Tethered il-9/il-9r and related engineered cells and methods
TW202307210A (zh) Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
CN117157407A (zh) 编码ap-1转录因子的密码子优化的核苷酸序列
TW200904466A (en) Methods of treating inflammatory disorders using isoforms of receptor tyrosine kinases

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE

Free format text: FORMER NAME(S): SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)

FGA Letters patent sealed or granted (standard patent)